Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury
- 8 October 2010
- journal article
- Published by Elsevier BV in Brain Research
- Vol. 1355, 189-194
- https://doi.org/10.1016/j.brainres.2010.07.080
Abstract
Since several different pathways are involved in cerebral ischemia/reperfusion injury, combination therapy rather than monotherapy may be required for efficient neuroprotection. In this study, we examined the protective effects of an apoptosis inhibitor Gly14-humanin (HNG) and a necroptosis inhibitor necrostatin-1 (Nec-1) on hypoxia/ischemia/reperfusion injury. Cultured mouse primary cortical neurons were incubated with Nec-1, HNG or both in a hypoxia chamber for 60 min. Cell viability was determined by MTS assay at 24 h after oxygen-glucose deprivation (OGD) treatment. Mice underwent middle cerebral artery occlusion for 75 min followed by 24 h reperfusion. Mice were administered HNG and/or Nec-1 (i.c.v.) at 4 h after reperfusion. Neurological deficits were evaluated and the cerebral infarct volume was determined by TTC staining. Nec-1 or HNG alone had protective effects on OGD-induced cell death. Combined treatment with Nec-1 and HNG resulted in more neuroprotection than Nec-1 or HNG alone. Treatment with HNG or Nec-1 reduced cerebral infarct volume from 59.3 ± 2.6% to 47.0 ± 2.3% and 47.1 ± 1.5%, respectively. Combined treatment with HNG and Nec-1 improved neurological scores and decreased infarct volume to 38.6 ± 1.5%. In summary, we demonstrated that the combination treatment of HNG and Nec-1 conferred synergistic neuroprotection on hypoxia/ischemia/reperfusion injury in vitro and in vivo. These findings provide a novel therapeutic strategy for the treatment of stroke by combining anti-apoptosis and anti-necroptosis therapy.Keywords
This publication has 19 references indexed in Scilit:
- The role of PARP activation in glutamate-induced necroptosis in HT-22 cellsBrain Research, 2010
- Mechanisms, challenges and opportunities in strokeNature Reviews Neuroscience, 2003
- Toward Wisdom From FailureStroke, 2002
- Neuroprotection is unlikely to be effective in humans using current trial designs.Stroke, 2002
- Synergistic effects of caspase inhibitors and MK‐801 in brain injury after transient focal cerebral ischaemia in miceBritish Journal of Pharmacology, 1998
- Systematic review of evidence on thrombolytic therapy for acute ischaemic strokeThe Lancet, 1997
- Synergistic Effects of Citicoline and MK-801 in Temporary Experimental Focal Ischemia in RatsStroke, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats.Stroke, 1994
- Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in CultureCancer Communications, 1991